Skip to main content
Triangle logo TriangleGet started

Cisplatin (NCT02734537)

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery: a one-minute explainerNCT027345371 min

Cisplatin trial for Head and Neck Squamous Cell Carcinoma (NCT02734537). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults after complete surgery for stage III or IVA squamous-cell cancer of the mouth, throat or voice box. Oropharyngeal cancers must be p16-negative. Positive surgical margins and extranodal extension are excluded.

The idea: compare six weeks of radiation alone with radiation plus weekly intravenous cisplatin. Radiation damages cancer cells; cisplatin interferes with their growth. Random assignment selects treatment. Tumor TP53 testing is required, but a mutation is not required. Researchers track recurrence and survival.

This phase 2 study plans 189 patients. ECOG-ACRIN sponsors it; 463 US sites are recruiting.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.